ClinicalTrials.gg
Status unknownNCT04545359NEURORELAXUpdated Sep 11, 2020

Study on Neurofeedback and Relaxation

An interventional study of Alpha-based neurofeedback and Sham neurofeedback in Healthy People, sponsored by Centre National de la Recherche Scientifique, France. Status unknown at 1 site in France. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-09-11.

Sponsored by Centre National de la Recherche Scientifique, France · Not applicable, Interventional, and Basic science

How we know

The sponsor has not verified this record recently (last verified Sep 2020), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Dec 2018, registered Mar 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This longitudinal study deals with the characterization of the electrophysiological and behavioral effects of alpha-based neurofeedback training on the brain networks involved in the relaxation process of healthy people.

Read the detailed description

Despite a growing number of studies dedicated to neurofeedback, the underlying cerebral mechanisms (plasticity phenomena underlying neurofeedback training or learning) are very poorly known. In most of the work on stress and anxiety reduction, the neural parameters on which neurofeedback is performed are low frequency waves like alpha waves. But the effects that an alpha-based neurofeedback has on these waves and more generally on the oscillatory behaviour of the networks involved after the neurofeedback sessions, are very little studied.

Thus, the NEURORELAX study aims to clarify the effects on neurofeedback training at the (electro)physiological level (changes in brain responses in terms of frequency of oscillations, power and location of the cerebral sources of these activities) and/or behavioural level (relaxation and reduced susceptibility to anxiety). It will use the Melomind neurofeedback device as built by myBrain Technologies company, which will make it additionally possible to assess feasibility of neurofeedback training with this reduced mobile device comprising of 2 dry electrodes. For these purposes, the investigators will propose a series of auditory neurofeedback training sessions to the participants, accompanied by electrophysiological (EEG) and clinical measures. The level of relaxation of the subjects will be characterized by self-reported questionnaires and by electrophysiological signal measurement.

02

Conditions studied

  • Healthy People

Keywords

  • Neurofeedback
  • Electroencephalography (EEG)
  • Alpha rhythm
  • Relaxation
  • Melomind device
  • Longitudinal analysis
03

In context

Lead sponsor

Centre National de la Recherche Scientifique, France is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntary adult subjects, aged 18 to 60
  • No known neurological history
  • Having an anxiety level higher than 35 on the STAI-YA scale
  • Insured under the French social security system
  • Signature of the
  • Absence of visual, hearing, sensory or motor deficits incompatible with participation in the study

Exclusion criteria

Exclusion Criteria:

  • recreational use of psychotropic drugs
  • ongoing anxiolytic / benzodiazepine treatment
  • current depressive episode and/or generalized anxiety troubles
  • person under guardianship, curatorship or safeguarding of justice or any other measure
  • administrative or judicial deprivation of rights or liberty
  • pregnant or breastfeeding
  • unable to give consent
  • person subject to a period of exclusion from further research
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Neurofeedback Group

    Participants from this group perform actual neurofeedback training, i.e they are instructed to control -- decrease -- in real-time a sound that is inversely related to the amplitude of their own alpha activity, obtained from Melomind EEG signals.

    Behavioral: Alpha-based neurofeedback

  • Sham comparator
    Control Group

    Participants from this group perform sham neurofeedback based on the feedback sounds generated by the participants from the Neurofeedback Group at the same step of the training program.

    Behavioral: Sham neurofeedback

Interventions

  • BehavioralAlpha-based neurofeedback

    Twelve 21-minute sessions (minimum of 1 session and maximum of 3 sessions per week) of auditory alpha-based neurofeedback with the Melomind device developed by myBrain Technologies (France). Recording of felt relaxation, perceived stress level, anxiety level pre-post sessions. Electrophysiological: Recording of EEG signals on 32 electrodes every two sessions.

  • BehavioralSham neurofeedback

    Twelve 21-minute sessions (minimum of 1 session and maximum of 3 sessions per week) of an auditory sham neurofeedback with the Melomind device developed by myBrain Technologies (France). Sham feedback is based on the real feedback of the participants in the Experimental arm. Recording of felt relaxation, perceived stress level, anxiety level pre-post sessions. Electrophysiological: Recording of EEG signals on 32 electrodes every two sessions.

06

What researchers measure

Primary outcomes

  1. Change in alpha frequency band power at the end of the 12 neurofeedback training sessions relative to the initial, pre-training, alpha power level.

    Individual EEG power measures in alpha band (between 7 and 13 Hz), performed over several minutes at rest, pre- and post-training, on every session.

    Time frame: From the 1st training session until the end of the 12th training session, the time frame of the assessment is 22 days minimum and 96 days maximum, with a minimum of 1 training session and a maximum of 3 training sessions per week.

  2. Change in alpha frequency band power at post-training relative to pre-training across every training session.

    Individual EEG power measures in alpha band (between 7 and 13 Hz), performed over several minutes at rest, pre- and post-training, on every session.

    Time frame: From the 1st training session until the end of the 12th training session, the time frame of the assessment is 22 days minimum and 96 days maximum, with a minimum of 1 training session and a maximum of 3 training sessions per week.

Secondary outcomes

  1. Change in the EEG power spectrum at the end of the 12 neurofeedback training sessions relative to the initial, pre-training, EEG spectral content.

    EEG signal measurement performed over several minutes at rest, pre- and post-training, on every session; EEG power spectrum analysis between 0.5 and 45 Hz.

    Time frame: From the 1st training session until the end of the 12th training session, the time frame of the assessment is 22 days minimum and 96 days maximum, with a minimum of 1 training session and a maximum of 3 training sessions per week.

  2. Change in the EEG power spectrum at post-training relative to pre-training across every training session.

    EEG signal measurement performed over several minutes at rest, pre- and post-training, on every session; EEG power spectrum analysis between 0.5 and 45 Hz.

    Time frame: From the 1st training session until the end of the 12th training session, the time frame of the assessment is 22 days minimum and 96 days maximum, with a minimum of 1 training session and a maximum of 3 training sessions per week.

  3. Change in anxiety trait after the 12 neurofeedback training sessions relative to before the first training session.

    Anxiety trait level measured by the State-Trait Anxiety Inventory (Trait evaluation, STAI-YA), before the 1st neurofeedback training session and after the last neurofeedback training session.

    Time frame: Assessments are performed before the 1st training session (at day 1) and after the 12th training session (at day 22 up to 96, depending on the number of training sessions per week (1 minimum, 3 maximum)).

  4. Change in affective state after the 12 neurofeedback training sessions relative to before the first training session.

    Affective state measured by the Positive and Negative Affect Schedule (PANAS), before the 1st neurofeedback training session and after the last neurofeedback training session.

    Time frame: Assessments are performed before the 1st training session (at day 1) and after the 12th training session (at day 22 up to 96, depending on the number of training sessions per week (1 minimum, 3 maximum)).

  5. Change in stress level after the 12 neurofeedback training sessions relative to before the first training session.

    Subjective stress level measured by the Perceived Stress Scale (PSS), before the 1st neurofeedback training session and after the last neurofeedback training session.

    Time frame: Assessments are performed before the 1st training session (at day 1) and after the 12th training session (at day 22 up to 96, depending on the number of training sessions per week (1 minimum, 3 maximum)).

  6. Changes in anxiety state at post-training relative to pre-training across every training session.

    Anxiety state level measured by the State-Trait Anxiety Inventory (State evaluation, STAI-YB) before and after every training session.

    Time frame: Assessments are performed before and after every training session; the estimated period of time of assessment is 22 days minimum and 96 days maximum, with a minimum of 1 training session and a maximum of 3 training sessions per week.

  7. Change in relaxation state at post-training relative to pre-training across every training session.

    Subjective relaxation state measured by a visual analog scale before and after every training session.

    Time frame: Assessments are performed before and after every training session; the estimated period of time of assessment is 22 days minimum and 96 days maximum, with a minimum of 1 training session and a maximum of 3 training sessions per week.

  8. Correlation between the changes in electrophysiological measurements and the changes in behavioral measures.

    Correlation between EEG power spectrum features and scores at behavioral questionnaires and scales, across training sessions.

    Time frame: From the 1st training session until the 12th training session (minimum of 22 days and maximum of 96 days, with a minimum of 1 training session and a maximum of 3 training sessions per week).

  9. Changes in EEG power spectrum during the training sessions from the 1st until the 12th sessions.

    EEG signal measured continuously during the 21 minutes of neurofeedback training, on every session; EEG power spectrum analysis between 0.5 and 45 Hz.

    Time frame: From the 1st training session until the 12th training session (minimum of 22 days and maximum of 96 days, with a minimum of 1 training session and a maximum of 3 training sessions per week).

07

Study locations

1 of 1 sites recruiting
  • Centre de Neuro-Imagerie de recherche (CENIR), ICM
    Paris, 75013, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2018 (actual). Primary completion is estimated for Sep 2021, 33 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2020
First posted
Sep 11, 2020
StartActual
Dec 12, 2018
Primary completionEst.
Sep 15, 2021
CompletionEst.
Sep 15, 2021
Last update
Sep 11, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04545359
Lead sponsor
Centre National de la Recherche Scientifique, France
Collaborators
Sorbonne University, Institut du Cerveau et de la Moelle Epinière, myBrain Technologies, Institut National de la Santé Et de la Recherche Médicale, France
Responsible party
Philippe Fossati (University Professor and Hospital Practitioner in psychiatry, Assistance Publique - Hôpitaux de Paris) — Principal investigator
First posted
Sep 11, 2020
Start date
Dec 12, 2018
Primary completion
Sep 15, 2021 (estimated)
Completion
Sep 15, 2021 (estimated)
Last update
Sep 11, 2020

Study contacts

Philippe Fossati, Pr
Contact
philippe.fossati@psl.aphp.fr
+33 1 42 16 28 70
Philippe Fossati, Pr
principal investigator · Equipe CIA, ICM GH Pitié-Salpêtrière 47 Bd de l'Hôpital 75651 Paris Cedex 13
Nathalie George, Dr
principal investigator · CNRS, CENIR MEG-EEG, ICM
Laurent Hugueville
principal investigator · CNRS, CENIR MEG-EEG, ICM
Jean-Yves Rotgé, Dr, MD
principal investigator · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion